Sickle cell disease (SCD) is associated with intravascular hemolysis and oxidative inhibition of nitric oxide (NO) signaling. BAY 54-6544 is a small-molecule activator of oxidized soluble guanylate cyclase (sGC), which, unlike endogenous NO and the sGC stimulator, BAY 41-8543, preferentially binds and activates heme-free, NO-insensitive sGC to restore enzymatic cGMP production. We tested orally delivered sGC activator, BAY 54-6544 (17 mg/kg/d), sGC stimulator, BAY 41-8543, sildenafil, and placebo for 4-12 weeks in the Berkeley transgenic mouse model of SCD (BERK-SCD) and their hemizygous (Hemi) littermate controls (BERK-Hemi). Right ventricular (RV) maximum systolic pressure (RVmaxSP) was measured using micro right-heart catheterization. RV hypertrophy (RVH) was determined using Fulton's index and RV corrected weight (ratio of RV to tibia). Pulmonary artery vasoreactivity was tested for endothelium-dependent and - independent vessel relaxation. Right-heart catheterization revealed higher RVmaxSP and RVH in BERK-SCD versus BERK-Hemi, which worsened with age. Treatment with the sGC activator more effectively lowered RVmaxSP and RVH, with 90-day treatment delivering superior results, when compared with other treatments and placebo groups. In myography experiments, acetylcholine-induced (endothelium dependent) and sodium-nitroprusside-induced (endothelium independent NO donor) relaxationof thepulmonary artery harvested from placebo-treated BERK-SCD was impaired relative to BERKHemi but improved after therapy with sGC activator. By contrast, no significant effect for sGC stimulator or sildenafil was observed in BERK-SCD. These findings suggest that sGC is oxidized in the pulmonary arteries of transgenic SCD mice, leading to blunted responses to NO, and that the sGC activator, BAY 54-6544, may represent a novel therapy for SCD-associated pulmonary arterial hypertension and cardiac remodeling.
Journal article
Nitric Oxide–Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease
American journal of respiratory cell and molecular biology, Vol.58(5), pp.636-647
05/2018
DOI: 10.1165/rcmb.2017-0292OC
Abstract
Details
- Title: Subtitle
- Nitric Oxide–Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease
- Creators
- Karin P. Potoka - Division of Newborn Medicine, Department of Pediatrics, Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineKatherine C. Wood - University of PittsburghJeffrey J. Baust - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineMarta Bueno - University of PittsburghScott A. Hahn - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineRebecca R. Vanderpool - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineTim Bachman - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineGrace M. Mallampalli - University of PittsburghDavid O. Osei-Hwedieh - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineValerie Schrott - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineBin Sun - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineGrant C. Bullock - Heart, Lung, Blood, and Vascular Medicine Institute, Department of MedicineEva-Maria Becker-Pelster - Bayer AG, Wuppertal, Germany, University of Witten/Herdecke, Witten, GermanyMatthias Wittwer - BayerJan Stampfuss - BayerIlka Mathar - BayerJohannes-Peter Stasch - Bayer AG, Wuppertal, Germany, University of Halle, Halle, GermanyHubert Truebel - BayerPeter Sandner - BayerAna L. Mora - University of PittsburghAdam C. Straub - University of PittsburghMark T. Gladwin - University of Pittsburgh
- Resource Type
- Journal article
- Publication Details
- American journal of respiratory cell and molecular biology, Vol.58(5), pp.636-647
- Publisher
- AMER THORACIC SOC; NEW YORK
- DOI
- 10.1165/rcmb.2017-0292OC
- ISSN
- 1044-1549
- eISSN
- 1535-4989
- Grant note
- National Institutes of Health grants: P01HL103455, R01 HL128304, R01 HL133864, K12 K12HD052892, L40 HL129422, P01 HL103455-06
This work was supported, in whole or in part, by National Institutes of Health grants P01HL103455 (M.T.G.), R01 HL128304 and R01 HL133864 (A.C.S.), K12 K12HD052892 and L40 HL129422 (K.P.P.) and P01 HL103455-06 (A.L.M.), and by the Bayer AG Vascular Diseases Research Group in accordance with a cooperative agreement between the University of Pittsburgh and Bayer AG.
- Language
- English
- Date published
- 05/2018
- Academic Unit
- Pathology
- Record Identifier
- 9984697738102771
Metrics
1 Record Views